Literature DB >> 6403647

Immune human lymphocytes produce an acid-labile alpha-interferon.

F R Balkwill, D B Griffin, H A Band, P C Beverley.   

Abstract

We have described in this paper a novel human interferon (IFN) with antigenic and cross-species reactivity of alpha-IFN and physicochemical properties of gamma-IFN. This IFN is produced by normal peripheral blood mononuclear cells during an immune response but has also been associated with autoimmune disease (10). The system described here will be useful in elucidating the biological significance and cell of origin of this IFN.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6403647      PMCID： PMC2186960          DOI： 10.1084/jem.157.3.1059

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  15 in total

1.  Affinity chromatography of human leukocyte and diploid cell interferons on sepharose-bound antibodies.

Authors:  K Berg; C A Ogburn; K Paucker; K E Mogensen; K Cantell
Journal:  J Immunol       Date:  1975-02       Impact factor: 5.422

2.  Immunology of interferons. I. Immune response to protective and nonprotective interferons.

Authors:  R E Levy-Koenig; M J Mundy; K Paucker
Journal:  J Immunol       Date:  1970-04       Impact factor: 5.422

3.  Tumour cell lines induce interferon in human lymphocytes.

Authors:  G Trinchieri; D Santoli; B B Knowles
Journal:  Nature       Date:  1977-12-15       Impact factor: 49.962

4.  HLA restriction of cell-mediated lysis of influenza virus-infected human cells.

Authors:  A J McMichael; A Ting; H J Zweerink; B A Askonas
Journal:  Nature       Date:  1977-12-08       Impact factor: 49.962

5.  Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon.

Authors:  O T Preble; R J Black; R M Friedman; J H Klippel; J Vilcek
Journal:  Science       Date:  1982-04-23       Impact factor: 47.728

6.  Determination of human leukocyte populations involved in production of interferons alpha and gamma.

Authors:  M Wiranowska-Stewart; W E Stewart
Journal:  J Interferon Res       Date:  1981-02

7.  Interferon-Like Virus-Inhibitor Induced in Human Leukocytes by Phytohemagglutinin.

Authors:  E F Wheelock
Journal:  Science       Date:  1965-07-16       Impact factor: 47.728

8.  Biological characteristics of cell line GL-V3 derived from the kidney of a vervet monkey (Cercopithecus aethiops).

Authors:  G J Christofinis
Journal:  J Med Microbiol       Date:  1970-05       Impact factor: 2.472

9.  Antigen-specific production of immune interferon by T Cells lines.

Authors:  J L McKimm-Breschkin; P L Mottram; W R Thomas; J F Miller
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

10.  Immune interferon produced to high levels by antigenic stimulation of human lymphocytes with influenza virus.

Authors:  F A Ennis; A Meager
Journal:  J Exp Med       Date:  1981-11-01       Impact factor: 14.307
View more
  5 in total

1.  Control of immune interferon release by cytotoxic T-cell clones specific for influenza.

Authors:  P M Taylor; D C Wraith; B A Askonas
Journal:  Immunology       Date:  1985-04       Impact factor: 7.397

2.  Serum levels of interferons in patients with systemic lupus erythematosus.

Authors:  T Kim; Y Kanayama; N Negoro; M Okamura; T Takeda; T Inoue
Journal:  Clin Exp Immunol       Date:  1987-12       Impact factor: 4.330

Review 3.  Interferons, a group of multiple lymphokines.

Authors:  H Kirchner
Journal:  Springer Semin Immunopathol       Date:  1984

4.  Interferon-gamma production by peripheral blood mononuclear cells from patients with Behçet's syndrome.

Authors:  T H Bacon; F Ozbakir; C A Elms; A M Denman
Journal:  Clin Exp Immunol       Date:  1984-09       Impact factor: 4.330

5.  Interferon-induced 2'-5' adenylate synthetase in vivo and interferon production in vitro by lymphocytes from systemic lupus erythematosus patients with and without circulating interferon.

Authors:  O T Preble; K Rothko; J H Klippel; R M Friedman; M I Johnston
Journal:  J Exp Med       Date:  1983-06-01       Impact factor: 14.307
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.